AstraZeneca PLC American Depositary Shares (AZN)
NASDAQ (NGS) NASDAQ (NGS) Primary 
3 Surprisingly Underrated Stocks to Buy Right Now
AstraZeneca is a healthcare giant trading at a discount. There's more to the story with Pfizer than its COVID woes and looming patent cliff.
Europe's Markets Are Cheap. 4 Stocks to Play.
Nevertheless, its member economies are poised for a rebound.
AstraZeneca Shares Fall Despite EPS Beat and Raised Guidance
AstraZeneca PLC NASDAQ: AZN is a United Kingdom-based healthcare firm and the sixth-largest pharmaceutical company in the world by market capitalization. So far, in 2024, the firm has outperformed the market and its sector, achieving a total return of 17%.
7 Explosive Growth Stocks Set to Soar in 2024
Wall Street has rewarded certain growth stocks handsomely this year. I believe now may be an opportune time to buy some of these high-flyers, even after the recent tech selloff.
Govt body's procedures means people with cancer aren't getting drug - AstraZeneca boss
The chief executive of AstraZeneca has criticised a public health body for refusing to make one of its breast cancer treatments available to NHS patients in England and Wales.
Why AstraZeneca Stock Is Sliding Today
AstraZeneca topped Wall Street revenue and earnings estimates. The big pharma company also raised its full-year revenue and earnings guidance.
Astrazeneca (AZN) Reports Q2 Earnings: What Key Metrics Have to Say
The headline numbers for Astrazeneca (AZN) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AstraZeneca (AZN) Beats on Q2 Earnings & Sales, Ups '24 View
AstraZeneca (AZN) reports encouraging Q2 results. It also raises its financial guidance for the full year on the back of strong demand for its marketed products.
AstraZeneca Posts Earnings Beat, Lifts Guidance on Strong Sales
AstraZeneca (AZN) posted better-than-expected results for the second quarter and lifted its full-year guidance Thursday as revenue grew in nearly all of its product categories compared to the same time last year.
AstraZeneca ups annual guidance as first half half revenues surge
AstraZeneca PLC (LSE:AZN) has raised its guidance for revenue and earnings this year after first-half sales jumped by 18%. Pascal Soriot, chief executive, said: "Building on our strong growth in the first half of the year and continued underlying demand for our medicines we are upgrading our FY 2024 guidance for both Total Revenue and Core EPS.
AstraZeneca lifts full-year outlook on upbeat demand for therapies
Anglo-Swedish drugmaker AstraZeneca on Thursday raised its sales and profit forecast for 2024 and topped analyst expectations for second-quarter revenue, buoyed by demand for its therapies for cancer and rare diseases.
Is AstraZeneca (AZN) a Portfolio Must-Have Pre-Q2 Earnings?
Sales of AstraZeneca's (AZN) key drugs like Imfinzi and Farxiga are expected to have been boosted by approvals in new indications.
